Drug intelligence / Profile preview

AX 313

Development stage: Unknown
Lead developer: Spruce Biosciences

Overview

AX 313 is a code name for a pharmaceutical drug in development by Allievex Corp. Specific details regarding its mechanism of action, primary indication, and current development status are not publicly available. Allievex Corp. is a biopharmaceutical company focused on developing therapies for rare pediatric neurodegenerative diseases. While the company is known for its work on tralesinidase alfa (also known as AX 250 or BMN 250) for Mucopolysaccharidosis Type IIIB, AX 313 is listed as a separate entity within their drug pipeline.

Targets

IGF2R (Cation-independent mannose-6-phosphate receptor)SGSH (N-sulphoglucosamine sulphohydrolase)NAGLU (Alpha-N-acetylglucosaminidase)

Beyond the preview

Go deeper on AX 313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AX 313.

Explore the full profile